PROCEPT BioRobotics (PRCT) Cost of Revenue (2020 - 2026)

PROCEPT BioRobotics (PRCT) has reported Cost of Revenue for 7 consecutive years, with $32.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 17.07% year-over-year to $32.1 million in Q2 2026; TTM through Jun 2026 was $120.7 million, a 22.58% increase from a year earlier, with the FY2025 full-year figure at $111.8 million, up 27.95% from the prior year.
• Cost of Revenue was $32.1 million for Q2 2026 at PROCEPT BioRobotics, up from $29.2 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $32.1 million in Q2 2026 and troughed at $6.5 million in Q1 2022.
• A 5-year average of $20.2 million and a median of $21.7 million in 2024 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 133.03% in 2022 and rose 10.02% in 2024, its largest moves.
• Over 5 years, Cost of Revenue stood at $13.1 million in 2022, then soared by 70.41% to $22.3 million in 2023, then increased by 10.02% to $24.6 million in 2024, then gained by 22.41% to $30.1 million in 2025, then grew by 6.81% to $32.1 million in 2026.
• The last three Cost of Revenue figures came in at $32.1 million (Q2 2026), $29.2 million (Q1 2026), and $30.1 million (Q4 2025), per Business Quant data.